Items Tagged ‘Carcinoma In Situ Breast cancer’

January 25th, 2016

ASCO Publishes Breast Cancer Survivorship Guidelines

By

The American Society of Clinical Oncology (ASCO), in collaboration with the American Cancer Society (ACS), have released updated guidelines regarding follow-up care for breast cancer survivors. The updated guidelines were recently published in the Journal of Clinical Oncology. There is an estimated 3.1 million breast cancer survivors alive today in the United States. At present, […]

View full entry

Tags: ACS, American cancer society, American Society of Clinical Oncology, Breast Cancer, Carcinoma In Situ Breast cancer, follow-up, guidelines, Inflammatory Breast Cancer, Metastatic Breast Cancer, News, Recurrent Breast Cancer, Screening/Prevention Breast Cancer


January 20th, 2016

Quality of Life Helps Determine Type of Hormone Treatment in Early Breast Cancer

By

Quality of life issues and different side effects caused by treatment may help determine which type of hormone therapy is most appropriate for postmenopausal women with ductal carcinoma in situ, particularly among women 60 years of age or older. These results were recently published in The Lancet. Hormone-positive breast cancers, which comprise approximately 75% of […]

View full entry

Tags: anastrozole, Arimidex, Breast Cancer, Carcinoma In Situ Breast cancer, DCIS, News, tamoxifen


October 1st, 2015

Radiation Essential to Controlling Long-Term Recurrence in Women With Early Form of Breast Cancer

By

Doctors have reported that rates of breast cancer recurrences continue to increase, even after 12 years, among patients with ductal carcinoma in situ (DCIS) who do not receive radiation therapy as part of their treatment regimen. These results were recently published in the Journal of Clinical Oncology. DCIS is considered to be the earliest type […]

View full entry

Tags: Breast Cancer, Carcinoma In Situ Breast cancer, DCIS, News, radiation, recurrence, Recurrent Breast Cancer, study


September 8th, 2015

Biomarker May Help Improve Treatment of Triple-Negative Breast Cancer

By

Researchers have found a biomarker that appears active in the growth and spread of triple-negative breast cancer. Known as interleukin-13 receptor alpha 2 (IL13Ralpha2), the biomarker may help doctors identify patients at high risk of disease spread and potentially provide a target for treatment. These findings were reported in Breast Cancer Research. The majority of […]

View full entry

Tags: biomarker, Breast Cancer, Carcinoma In Situ Breast cancer, HER2-negative, IL13Ralpha2, News, Stage I Node Negative Breast Cancer, Stages II-III Breast Cancer, Triple Negative Breast Cancer


September 1st, 2015

Women with Early Breast Cancer Have Fewer Side Effects with Shorter Courses of Radiation

By

Women with early breast cancer have fewer side effects when they’re treated with shorter courses of radiation at higher doses than with conventional radiation to the whole breast. These findings were reported in JAMA Oncology.[1] Treatment with shorter course of radiation at higher doses is known as hypofractionated radiation therapy. This approach allows for less […]

View full entry

Tags: Breast Cancer, Carcinoma In Situ Breast cancer, conventional radiation, DCIS, hypofractionated radiation therapy, News, radiation, Stage I, Stage I Node Negative Breast Cancer, Stage II, Stages II-III Breast Cancer


August 27th, 2015

Breast Cancer Research and Treatment Publishes Oncotype DX(R) DCIS Score(TM) Study Conducted in Canada

By

Genomic Health, Inc. (Nasdaq: GHDX) announced that Breast Cancer Research and Treatment published results from a second large clinical validation study of Oncotype DX® in patients with stage 0 breast cancer, also known as DCIS (Ductal Carcinoma In Situ). The population-based study, conducted by the Ontario DCIS Study Group, reconfirmed that the Oncotype DX DCIS […]

View full entry

Tags: Breast Cancer, Carcinoma In Situ Breast cancer, clinical trial, DCIS, genomic study, News, personalized treatment


June 9th, 2015

Arimidex® More Effective than Tamoxifen in Prevention of Recurrence in Early Breast Cancer

By

For patients with a common type of breast cancer known as ductal carcinoma in situ (DCIS), the drug Arimidex® (anastrozole) may provide better protection against recurrence than tamoxifen. These findings were presented at 2015 Annual Meeting of the American Society of Clinical Oncology (May 29–June 2, Chicago, Illinois) and published in the Journal of Clinical […]

View full entry

Tags: anastrozole, Arimidex, Breast Cancer, Carcinoma In Situ Breast cancer, DCIS, ductal carcinoma in situ, News, tamoxifen


January 27th, 2015

Breast Cancer Research: Have We Made Progress?

By

Published results from research studies in breast cancer in the last year represent several practice changing milestones. CancerConnect News coverage of advances in the management of breast cancer included the following key developments: 2014: Have we Made Progress? Recent Study Finds That African American Women Less Likely To Receive Standard Breast Cancer Treatment Breast Cancer […]

View full entry

Tags: Breast Cancer, breast cancer research, Carcinoma In Situ Breast cancer, Inflammatory Breast Cancer, Metastatic Breast Cancer, News, Recurrent Breast Cancer, Screening/Prevention Breast Cancer, Stage I Node Negative Breast Cancer, Stages II-III Breast Cancer, Supportive Care Breast Cancer


October 15th, 2014

Ask the Expert: Making Informed Decisions about Early-Stage Breast Cancer Treatment

By

October 23, 2014 at 6:00pm EDT CancerConnect live Web Chat with an Expert sereis presents: “Rethink Pink: From Awareness to Knowledge, Advice for women newly diagnosed with early stage breast cancer.” On October 23, 2014 at 6:00pm EDT you will have the opporutnity to engage with a breast cancer expert who will discuss and answer […]

View full entry

Tags: Breast Cancer, Carcinoma In Situ Breast cancer, News, Stage I Node Negative Breast Cancer


September 24th, 2014

Walk or Run Your Way to a Reduced Risk of Breast Cancer

By

Want to reduce your risk of breast cancer? Lace up those shoes and get moving—because exercise has a significant impact. There is a growing body of evidence to indicate that exercise is crucial to reducing the risk of cancer. Now a new study has put a number on that reduced risk: 41.5 percent.1 That’s right: […]

View full entry

Tags: Breast Cancer, Carcinoma In Situ Breast cancer, exercise, Inflammatory Breast Cancer, Metastatic Breast Cancer, News, Recurrent Breast Cancer, Screening/Prevention Breast Cancer, Stage I Node Negative Breast Cancer, Stages II-III Breast Cancer


September 17th, 2014

Breast Conservation Therapy May Be Better than a Mastectomy

By

Breast cancer claims the lives of approximately 40,000 women annually in the United States alone. Early-stage breast cancer refers to cancer that has not spread from its site of origin. Patients with early-stage breast cancer have a high cure rate with current standard treatment options, particularly those that do not have cancer that has spread […]

View full entry

Tags: Breast Cancer, Carcinoma In Situ Breast cancer, mastectomy, News, Stage I Node Negative Breast Cancer, Stages II-III Breast Cancer, surgery


August 28th, 2014

Risk of Breast Cancer Recurrence Doesn’t Increase with TNF Inhibitor Use

By

According to the results of a recently published study from Swedish investigators treatment with tumor necrosis factor inhibitors (TNF) does not appear to increase the rate of breast cancer recurrence among patients with rheumatoid arthritis (RA).  The study’s results should help to allay any concerns about the potential for tumor necrosis factor (TNF) inhibitors to […]

View full entry

Tags: Breast Cancer, Carcinoma In Situ Breast cancer, Inflammatory Breast Cancer, News, RA, Recurrent Breast Cancer, Screening/Prevention Breast Cancer, Stage I Node Negative Breast Cancer, Stages II-III Breast Cancer, Supportive Care Breast Cancer, TNF


July 7th, 2014

Recent Study Finds That African American Women Less Likely To Receive Standard Breast Cancer Treatment

By

New research from the The University of Texas MD Anderson Cancer Center found that African American women diagnosed with early stage invasive breast cancer were 12 percent less likely than Caucasian women with the same diagnosis to receive axillary sentinel lymph node (SLN) biopsy, a minimally invasive technique, which has become the standard surgical procedure. […]

View full entry

Tags: Breast Cancer, Carcinoma In Situ Breast cancer, disparity, News, Stage I Node Negative Breast Cancer, Stages II-III Breast Cancer


June 30th, 2014

Zoladex Shows Fertility Advantages in Treatment of Early Breast Cancer

By

At the 2014 American Society of Clinical Oncology® meeting in Chicago, researchers reported that women with early stage hormone receptor-negative (HR-negative) breast cancer who were treated with Zoladex® (goserelin) had a reduced rate of ovarian failure at 2 years. In addition, the Zoladex group had higher rates of patients becoming pregnant, patients giving birth, and […]

View full entry

Tags: Breast Cancer, Carcinoma In Situ Breast cancer, fertility, News, Stage I Node Negative Breast Cancer, Stages II-III Breast Cancer, zoladex


June 18th, 2014

Ask the Expert: Making Informed Decisions about Breast Reconstruction

By

July 16, 2014 at 6:30pm EST CancerConnect live Web Chat with an Expert series presents:  “Making Informed Decisions about Breast Reconstruction.”  On July 16, 2014 at 6:30pm EST you will have the opportunity to engage with a breast cancer expert who will discuss and answer participants’ questions about reconstruction after breast cancer surgery during a […]

View full entry

Tags: Breast Cancer, breast reconstruction, Carcinoma In Situ Breast cancer, Inflammatory Breast Cancer, News, Recurrent Breast Cancer, Stage I Node Negative Breast Cancer, Stages II-III Breast Cancer, Supportive Care Breast Cancer, surgery